Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY: JNJ )

164.16 -0.66 (-0.40%)
Official Closing Price Updated: 6:30 PM EDT, Sep 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 11,834,953
Open 164.30
Bid (Size) 163.90 (1)
Ask (Size) 164.12 (1)
Prev. Close 164.82
Today's Range 163.55 - 164.87
52wk Range 143.13 - 168.85
Shares Outstanding 2,628,679,824
Dividend Yield 2.90%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Johnson & Johnson Announces that its Subsidiary, Red River Talc LLC, has Filed a Voluntary Prepackaged Chapter 11 Case to Resolve All Current and Future Ovarian Cancer Talc Claims
From Johnson & Johnson
Via Business Wire
Johnson & Johnson's Rybrevant Scores Third FDA-Approval Of 2024 For Certain Type Of Inoperable Lung Cancer In Pretreated Patients
Johnson & Johnson's Rybrevant (amivantamab) received FDA approval for use with standard chemotherapy in advanced non-small cell lung cancer with specific EGFR mutations. 
Via Benzinga
Exposures Product Safety

Performance

YTD
+2.62%
+2.62%
1 Month
+2.50%
+2.50%
3 Month
+11.08%
+11.08%
6 Month
+5.40%
+5.40%
1 Year
+0.77%
+0.77%

More News

Read More
Zevra Therapeutics' Drug Becomes First FDA-Approved Treatment For Ultra-Rare Neurodegenerative Disease
Via Benzinga
Exposures Product Safety
The Latest Analyst Ratings For Johnson & Johnson
Via Benzinga
2024 Election: Drug Prices Remain A 'Hot Topic.' Can Pharma Stocks Withstand The Pressure?
Via Investor's Business Daily
Unpacking the Latest Options Trading Trends in Johnson & Johnson
Via Benzinga
Competitor Analysis: Evaluating Johnson & Johnson And Competitors In Pharmaceuticals Industry
Via Benzinga
2 Vanguard Index Funds Could Turn $400 Per Month Into $16,800 in Annual Dividend Income by Retirement
Via The Motley Fool
Chinese Biotech BeiGene Labeled 'Unique Investment' As Analyst Confident In Lead Cancer Drug
Via Benzinga
Top 3 Dividend Stocks to Beat Market Volatility and Boost Returns
Via MarketBeat
Topics Economy
Exposures Economy Interest Rates
Time To Invest And Or Trade In Bio-Tech Stocks?
Via Talk Markets
Topics ETFs
Should You Buy Novavax Stock After This Regulatory Win?
Via The Motley Fool
How To Earn $500 A Month From Johnson & Johnson Stock
Via Benzinga
Metals in Tampons: FDA Initiates New Safety Measures and Testing
Via Benzinga
Exposures Product Safety
Sony Music-Universal Music JV Hits Johnson & Johnson With Copyright Lawsuit Over Unlicensed Music Use Covering 80 Videos
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Johnson & Johnson's Mid-Stage Lung Cancer Trial Reveals Fewer Infusion-Related Reactions
Via Benzinga
3 Safe Stocks with Safe Dividends for Your Portfolio
Via MarketBeat
Topics Economy
Exposures Economy
Is Hims & Hers Health the Next Teladoc?
Via The Motley Fool
Exposures COVID-19
2 Stocks That Are Passive Income Machines to Buy and Hold Forever
Via The Motley Fool
Protagonist Therapeutics' Two Investigational Candidates Target Over $10B Market, Bullish Analyst Opines
Via Benzinga
Kenvue Set To Pop Like A Tylenol Gelcap? Golden Cross Looms On Stock Chart
Via Benzinga
Dell, CoStar, PayPal And A Major Health Care Stock On CNBC's 'Final Trades'
Via Benzinga
Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields
Via Benzinga
Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results
From Johnson & Johnson
Via Business Wire
Johnson & Johnson Raises Talc Settlement Offer to $9B, Moves Closer to Settlement Victory
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.